A 2019 TOP DOC
Dr. Sandy Kotiah serves as the Director of The Neuroendocrine Tumor Center at Mercy and leads a multidisciplinary team of doctors focused on providing some of the best treatment options for rare neuroendocrine diseases.
Inflammatory bowel disease, or IBD, includes disorders that cause inflammation of the intestines. IBD is treated at Mercy by expert gastroenterologists.
The Institute for Foot and Ankle Reconstruction at Mercy offers a top rated team of surgeons, dedicated to advanced treatments of common and complex foot and ankle disorders.
Mercy offers emergency care on the Downtown Baltimore campus 24 hours a day, 7 days a week (410-332-9477) with access to a trained emergency medicine team, diagnostic services and consultations with specialists.
In case of an Emergency, Dial 911 and follow the instructions of the EMS (Emergency Medical Services) team.
Mercy Medical Center's downtown campus includes our Main Hospital - The Mary Catherine Bunting Center, McAuley Plaza and The Weinberg Center.
General visiting hours at Mercy are 11:00 am to 8:30 pm. Hours vary by floor, please check with the nursing staff or call 410-332-9555.
Currently Displaying: Active Clinical Trials
The Phase 3 study is to confirm the efficacy of OTL38 in combination with fluorescent light to detect additional Folate Receptor-positive (FR+) ovarian cancer lesions not detected by palpation and visualization under normal light in patients with FR+ ovarian cancer scheduled to undergo primary surgical cytoreduction, interval debulking, or recurrent ovarian cancer surgery. (Clinicaltrials.gov ID#: NCT03180307)
The purpose of this phase II trial is to determine the toxicity and post-operative complications related to cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) as an initial treatment option for patients with ovarian, fallopian tube, or primary peritoneal cancers and its impact on quality of life. Subjects will be randomized to one of two treatment groups: CRS with HIPEC followed by combination chemotherapy, carboplatin and paclitaxel, or CRS only followed by combination chemotherapy carboplatin and paclitaxel.
Protocol Title and ClinicalTrials ID#:
A phase II randomized study: Outcomes after cytoreductive surgery (CRS) with or without carboplatin hyperthermic intraperitoneal chemotherapy (HIPEC) followed by systemic chemotherapy with carboplatin and paclitaxel as initial treatment of ovarian, fallopian tube, and primary peritoneal cancer. NCT02124421
The objective of this study is to collect patient specimens prospectively (tumor, blood, vaginal swab, and urine sample) from benign, high risk, and malignant surgeries in order to develop diagnostic biomarkers and targeted anticancer agents for gynecologic tumors. http://lifegenedna.com/
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects with Non Small Cell Lung Cancer, Ovarian Cancer or Breast Cancer. (Clinicaltrials.gov ID#: NCT03937154)
The Gynecologic Oncology Center at Mercy in Baltimore, Maryland is one of the top Gynecologic Cancer Centers in the region. Our gynecologic oncologists are dedicated to helping patients find the best care, treatment, and surgery options available for gynecologic cancers including ovarian cancer, cervical cancer and uterine cancer. We are proud to be a recognized leader in gynecologic robotic surgery as well as laparascopic and traditional surgery and remain dedicated to helping women find a cure for cancer.
Dr. Teresa Diaz-Montes is a gynecologic surgeon who provides expertise in gynecologic cancers as well as minimally invasive surgical techniques.